Ken Campbell, PhD (Faculty)
Charles Chung, PhD (Post doctoral fellow)
The Transplant Center collaborates with scientists in the
Department of Physiology and the
Center for Muscle Biology to study the molecular mechanisms underlying end-stage heart failure. The main goals are to predict, develop and test sarcomere level therapies for contractile dysfunction. For more information see the
Campbell lab website.
Campbell SG, Haynes P, Kelsey Snapp W, Nava KE & KS Campbell (2013). Altered ventricular torsion and transmural patterns of myocyte relaxation precede heart failure in aging F344 rats. American Journal of Physiology: Heart and Circulatory Physiology 305, H676-686.
Chung CS, Mitov MI, Callahan LA, & KS Campbell (2013). Increased myocardial short-range forces in a rodent model of diabetes reflect elevated content of beta myosin heavy chain. Archives of Biochemistry and Biophysics (in press).
Chung CS, Hutchinson KR, Methawasin M, Saripalli C, Smith JE 3rd, Hidalgo CG, Luo X, Labeit S, Guo C, Granzier HL. (2013) Shortening of the elastic tandem immunoglobulin segment of titin leads to diastolic dysfunction. Circulation 128(1):19-28.
The Liver Cancer Basic Science Research Laboratory (LCBSRL) at the University of Kentucky, has a mission of understanding the cellular and molecular basis of liver cancer as well as developing translational tools relevant for the treatment of the disease. In the last few years, our group has focused on the development of new molecular targeted therapies in hepatocellular carcinoma and liver cancer stem cells. To accomplish this, we have developed several research projects in a close partnership with the Markey Cancer Center, the Departments of Immunology and Microbiology, Physiology and Biochemistry. The scientific staff of the LCBSRL is a team of young, enterprising researchers that have been brought to this program by their unique interest in liver cancer research. It is also the mission of our lab to be a source of continuing medical education, training young scientists and advocates in liver cancer research.
Lung transplantation is currently the most effective treatment for selected patients with end-stage lung disease. However, donor lung scarcity has been a chronic issue. On average, approximately only a third of donor lungs are recovered from multiorgan donors. This is partly due to the organ’s susceptibility to injury during donor lung management in a brain dead donor.
Ex-Vivo Lung Perfusion (EVLP), where donor lungs are ventilated and perfused with acellular (non-blood) solution in a chamber, was introduced as a method to improve donor lung function and potentially increase the donor pool. This lung perfusion method, clinically applied by a group of University of Toronto, has demonstrated to improve the quality of donor lung that are deemed unacceptable as donor lung. Clinical trial is currently underway in several lung transplant centers in the United States. Attempts to improve donor lung function with this method have been made at Lung Transplant Program of University of Kentucky.